| CAS NO: | 1352792-74-5 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 348.42 |
|---|---|
| Formula | C20H16N2O2S |
| CAS No. | 1352792-74-5 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: ≥ 30mg/mL |
| Water: N/A | |
| Ethanol: N/A | |
| Chemical Name | 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid |
| Synonyms | RDEA-3170; RDEA3170; RDEA 3170 |
| SMILES Code | CC(C)(SC1=C(C2=C3C=CC=CC3=C(C#N)C=C2)C=NC=C1)C(O)=O |
| Target |
IC50: 25 nM (URAT1)[1] |
|---|---|
| In Vitro | Verinurad inhibits the transportation activity of human URAT1 in a dose-dependent manner with an IC50 of 25 nM [1]. |
| References |
[1]. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout. Sci Rep. 2017 Apr 6;7(1):665 |
m.cnreagent.com